Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives of Hikma Pharmaceuticals, headed by Mr. Tamer Gerdana, Chairman and Managing Director of Hikma Egypt. The meeting comes within the framework of the EDA’s periodic meetings with pharmaceutical companies operating in the Egyptian market, aimed at following up on sector developments and exploring avenues of joint cooperation in a manner that supports local manufacturing, encourages investment, and ensures the quality of pharmaceutical products circulating in the market in accordance with approved regulatory standards.
During the meeting, Dr. El-Ghamrawy emphasized the importance of continued cooperation and coordination with pharmaceutical companies to support the national pharmaceutical industry, ensure the sustainability of medicine availability, and maintain product quality. He highlighted the EDA’s commitment to developing regulatory policies, providing technical support, and creating a stimulating regulatory environment that contributes to protecting public health and serving the public interest.
Dr. El-Ghamrawy also noted that the Authority seeks to stimulate innovation in the pharmaceutical sector and encourage companies to invest in research and development, thereby contributing to the availability of advanced pharmaceutical products that meet the growing needs of the local market. This comes alongside strengthening regulatory oversight to ensure compliance with international standards, protect public health, and establish a stable and attractive investment environment.
For their part, Hikma’s representatives expressed their appreciation for the efforts of the Egyptian Drug Authority in developing the regulatory system and opening effective communication channels with pharmaceutical companies, which enhances market stability and encourages investment in the sector. The company also reaffirmed its commitment to complying with approved regulatory standards and supporting the State’s direction toward enhancing local manufacturing and providing safe and effective pharmaceutical products to meet patients’ needs.
The meeting reflects the Egyptian Drug Authority’s commitment to building an advanced and sustainable pharmaceutical system capable of keeping pace with global developments and strengthening Egypt’s position as a regional hub for pharmaceutical manufacturing. This, in turn, supports drug security, attracts further investments, and contributes to achieving sustainable development in the healthcare sector, positively impacting citizens’ health and the quality of services provided to them.